期刊
BLOOD
卷 115, 期 13, 页码 2704-2708出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-09-244525
关键词
-
类别
资金
- National Cancer Institute [5U01HL069294]
- National Heart, Lung and Blood Institute
- National Institute of Allergy and Infectious Diseases [U24-CA76518]
- Department of Health and Human Services [HHSH234200637015C]
- Office of Naval Research [N00014-06-1-0704, N00014-08-1-0058]
- AABB
- Aetna
- American Society for Blood and Marrow Transplantation
- Amgen Inc
- Medical College of Wisconsin
- Astellas Pharma US Inc
- Baxter International Inc
- Bayer HealthCare Pharmaceuticals
- Be the Match Foundation
- Biogen IDEC
- BioMarin Pharmaceutical Inc
- Biovitrum AB
- BloodCenter of Wisconsin
- Blue Cross and Blue Shield Association
- Bone Marrow Foundation
- Canadian Blood and Marrow Transplant Group
- CaridianBCT
- Celgene Corporation
- CellGenix GmbH
- Centers for Disease Control and Prevention
- Children's Leukemia Research Association
- ClinImmune Labs
- CTI Clinical Trial and Consulting Services
- Cubist Pharmaceuticals
- Cylex Inc
- CytoTherm
- DOR = BioPharma Inc
- Dynal Biotech, an Invitrogen Company
- Eisai Inc
- Enzon Pharmaceuticals Inc
- European Group for Blood and Marrow Transplantation
- Gamida Cell Ltd
- GE Healthcare
- Genentech Inc
- Genzyme Corporation
- Histogenetics Inc
- HKS Medical Information Systems
- Hospira Inc
- Infectious Diseases Society of America
- Kiadis Pharma
- Kirin Brewery Co Ltd
- Leukemia & Lymphoma Society
- Merck Company
- MGI Pharma Inc
- Michigan Community Blood Centers
- Millennium Pharmaceuticals Inc
- Miller Pharmacal Group
- Milliman USA Inc
- Miltenyi Biotec Inc
- National Marrow Donor Program
- Nature Publishing Group
- New York Blood Center
- Novartis Oncology
- Oncology Nursing Society
- Osiris Therapeutics Inc
- Otsuka America Pharmaceutical Inc
- Pall Life Sciences
- PDL BioPharma Inc
- Pfizer Inc
- Pharmion Corporation
- Saladax Biomedical Inc
- Schering Corporation
- Society for Healthcare Epidemiology of America
- StemCyte Inc
- StemSoft Software Inc
- Sysmex America Inc
- Teva Pharmaceutical Industries
- THERAKOS Inc
- Thermogenesis Corporation
- Vidacare Corporation
- Vion Pharmaceuticals Inc
- ViraCor Laboratories
- ViroPharma Inc
- Wellpoint Inc
- NATIONAL CANCER INSTITUTE [U24CA076518] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL069294] Funding Source: NIH RePORTER
Donor-directed human leukocyte antigen (HLA)-specific allo-antibodies (DSAs) cause graft failure in animal models of hematopoietic stem cell transplantation (HCT). Archived pretransplantation sera from graft failure patients (n = 37) and a matched case-control cohort (n = 78) were tested to evaluate the role of DSAs in unrelated donor HCT. Controls were matched for disease, disease status, graft type, patient age, and transplantation year. Patients had acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome; 98% received myeloablative conditioning regimens 100% received T-replete grafts, 97% received marrow, 95% HLA-mismatched, and 97% received calcineurin-based graft-versus-host disease prophylaxis. Among the 37 failed transplantations, 9 ( 24%) recipients possessed DSAs against HLA-A, B, and/or DP, compared with only 1 (1%) of 78 controls. Therefore, the presence of DSAs was significantly associated with graft failure (odds ratio = 22.84; 95% confidence interval, 3.57-infinity; P < .001). These results indicate that the presence of pretransplantation DSAs in recipients of unrelated donor HCT is associated with failed engraftment and should be considered in HCT donor selection. (Blood. 2010;115(13):2704-2708)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据